This has been a really busy week for Alzheimer’s news and the people living and working with different types of dementia’s! The International Conference on Alzheimer’s was held in Chicago Illinois, my home state, this past week. A lot of good information and many questions came out of it, so I thought I’d start the show today by talking about what the conference covers. I will address some of the big headlines that came out of it and what you need to know for clarification, so here we go! The conference is held once a year; 6000 researchers from about 33 different countries convene together with physicians who are neurologists and general practitioners, and anybody who’s interested in the subject of dementia diseases. They talk about what clinical trials are going on in their camps! Are they being successful, and what’s on the horizon? I think some real hopeful information came out of the conference this year!
I think I will just dive into a couple of the highlights, so off the top there is a drug called Biogen that’s currently in the clinical trial stages and researchers are working towards getting this drug through the trials and ready for the public. The Biogen trial is coming out of Boston – Harvard, with Dr. Reisa Spierling at the helm and we’re pretty excited about it and where they’re at with it right now. 900 people were targeted in this clinical trial and of course, we must always have a certain amount that are getting placebo for the study’s efficacy. Biogen did show some benefit removing the amyloid plaque that causes Alzheimer’s. Dr. Fargo, one of the main researchers in the Alzheimer’s Association, stated that the drug cleared some of the amyloid plaque in the folks who received it, and they did show some improved cognition as well. This is super exciting, although they are years away from this becoming a pharmaceutical drug, ensuring people will be able to buy it in pharmacies everywhere. This trial is in the very early steps, but we are thrilled it is showing some promise.
In Denver Dr. Huntington Potter is working on the Leukine trial, which was also celebrated at the International Conference. It is showing some promise as well. It’s a little farther behind the Biogen trial, but Dr. Potter is making some great steps forward in the fight to cure Alzheimer’s disease. With the recent information that $401 million is being put towards research from the NIH National Institutes of Health, Dr. Potter’s study is back up and rolling, on all cylinders, and we hopefully will have some good news out of his clinical trials shortly!
Another thing that people have asked me about: researchers at the conference were talking about MCI, mild cognitive impairment – which is pre-dementia. It’s also pre-Alzheimer’s pathology, focusing on people who are showing early, early, signs of loss of cognition, but is has not yet interfered with their activities of daily living. What they’re trying to work on regarding MCI, is having those folks have a healthier lifestyle, and seeing if researchers can somehow intervene and make some changes to their lives that would lower their risk of getting Alzheimer’s. We are not talking about prevention or reversal of the disease, but rather a lower risk of getting it and staving it off for little while with lifestyle changes and environmental changes.
A lot of the questions I received this week was the blood pressure (BP) issue. Yes, the researchers are targeting having more people with a blood pressure of 120, as the threshold used to be 140. Researchers are exploring the idea of people having a BP of 120 and taking good care of themselves, mind healthy, and body healthy, and if they do, it might lower their risk of getting Alzheimer’s or having it come on a little less strong, the younger that you are. So, we’re all about healthy body, healthy brain, but it doesn’t mean that we are reversing anything!
Last but not least,